PBMHealthcare · BiotechnologyTicker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 4 of 100 as at 28 Oct 2026 — in the weakest quartile.
Consensus tells you what everyone already believes. The model scores Psyence Biomedical Ltd. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Size (90): Smaller than most of the companies we track.
Quality (5): Profits are thin or unreliable for the size of the business, or they are not turning into cash.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on PBM, reported as data — targets and ratings, the market's view beside the model's.
We don’t hold enough price history for this company yet.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
PBM appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 73% of US stocks
Cheaper than 85% of US stocks
Cheaper than 69% of US stocks
Higher than 32% of US stocks
Higher than 30% of US stocks
Higher than 19% of US stocks
Higher than 13% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Psyence Biomedical Ltd. has a market value of $11.6M and an enterprise value of $6.5M.
Revenue in the twelve months to 30 Sept 2025: $0.0.
Net income over the same four quarters: −$1.1M.
Diluted earnings per share, trailing twelve months: $6.29.
Trailing P/E: 0.0×.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Psyence Biomedical Ltd. employs 12 people.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Psyence Biomedical Ltd. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Psyence Biomedical announced that both milestones tied to its backstop subscription commitment in Psyence Labs Ltd. were met, completing its Psyence Labs investment.
Why it matters — The announcement concerns PBM’s investment in Psyence Labs and milestones related to ibogaine.
Psyence BioMed announced a partnership with DEA-registered Benuvia Operations to establish a Texas-based manufacturing pathway for pharmaceutical-grade ibogaine, supporting its planned U.S. development program.
Why it matters — This gives Psyence BioMed a U.S. manufacturing route for pharmaceutical-grade ibogaine as it advances its domestic development efforts.
Psyence BioMed announced a binding term sheet with PsyLabs granting its Texas subsidiary exclusive U.S. development, supply and distribution rights to PsyLabs' pharmaceutical-grade ibogaine, subject to a definitive agreement.
Why it matters — A PBM watcher would care because this exclusive U.S. ibogaine licence expands Psyence BioMed's commercial pipeline and strengthens its foothold in the psychedelic therapeutics market.
Psyence BioMed announced a strategic ibogaine investment, including an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange. The company is also advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder and has established a dedicated U.S. subsidiary, Texas Ibogaine Research Corporation, for these activities.
Why it matters — PBM watchers would care because these transactions and the establishment of a U.S. subsidiary signal concrete progress toward the company's planned ibogaine clinical development in the United States.
Psyence Biomedical Ltd. established a Texas-based research corporation as a dedicated U.S. vehicle for regulated ibogaine development. The new entity is positioned to hold U.S. rights to PsyLabs' pharmaceutical-grade ibogaine, subject to definitive licensing, and is designed to coordinate supply, manufacturing, regulatory, and potential clinical development through a single U.S. entity with U.S.-based partners.
Why it matters — A PBM watcher would care because this move creates a dedicated U.S. structure to advance the company's ibogaine development, potentially strengthening its U.S. regulatory and commercial positioning.
As at 28 Oct 2026, Psyence Biomedical Ltd. ranks 4 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (90 of 100).
No analyst covering Psyence Biomedical Ltd. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for PBM are extrapolating price history, which says nothing about the business.
Psyence Biomedical Ltd. is a Toronto-based biopharmaceutical company focused on developing botanical psilocybin-based medicines for mental health and palliative care settings.
The most recent item we track (GlobeNewsWire, 21 Oct 2026): "Psyence BioMed Completes PsyLabs Investment as Ibogaine Milestones Are Met". Psyence Biomedical announced that both milestones tied to its backstop subscription commitment in Psyence Labs Ltd. were met, completing its Psyence Labs investment.
Psyence Biomedical Ltd. is a Toronto-based biopharmaceutical company focused on developing botanical psilocybin-based medicines for mental health and palliative care settings. The company’s current work centers on nature-derived psychedelic therapeutics designed to address unmet needs in conditions such as adjustment disorder, anxiety, depression, grief, and related psychological distress in patients facing serious illness. Its lead candidate is being evaluated in clinical studies as a capsule formulation of naturally sourced psilocybin, reflecting the company’s emphasis on standardized, non-synthetic drug development. Psyence Biomedical operates within the broader life sciences and healthcare markets, combining drug development, clinical research, and commercialization efforts around psychedelic medicine. Through this specialization, the company occupies a niche position in the emerging field of evidence-based psychedelic therapeutics, with a focus on supportive care applications rather than general consumer health products.
CEO Mr. Jody Aufrichtig · 12 employees · Canada · https://psyencebiomed.com